
Allopregnanolone identity-and-context orientation. The fused-ring model is not an atom-complete structure, and the plate does not show binding, channel state, dose, treatment response, mood, pregnancy, or diagnosis.
Scientific media record3 verified identifiers
- Subject
- Allopregnanolonebiological-process
- Review
- Editorial review completeIdentifiers authority-verified · Accessibility validated · · allopregnanolone|allopregnanolone-mechanism-v1.webp
- Digital source
- Trained-algorithmic mediaCreated with a trained generative algorithm and reviewed by WikiBiome for subject identity, scientific framing, identifiers, provenance, and accessibility.
- Scientific basis
- Allopregnanolone — PubChemAllopregnanolone — ChEBI
- License
- CC BY-SA 4.0Created
Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid metabolite of progesterone that is the most potent endogenous positive allosteric modulator of GABA-A receptors. It is central to the pathophysiology of PMDD and postpartum depression—conditions where abnormal sensitivity to allopregnanolone fluctuations drives mood dysregulation.
Evidence map3 cited passagesInspect provenance +
In PMDD, patients have paradoxical sensitivity to allopregnanolone—normal luteal phase rises in allopregnanolone trigger anxiety and dysphoria rather than the expected anxiolytic/sedative effect.
Brexanolone (IV allopregnanolone) is FDA-approved for postpartum depression; zuranolone (oral) extends this to MDD.
Postpartum depression correlates with the precipitous drop in allopregnanolone at delivery.
PMDD and PPD#
In PMDD, patients have paradoxical sensitivity to allopregnanolone—normal luteal phase rises in allopregnanolone trigger anxiety and dysphoria rather than the expected anxiolytic/sedative effect.[1]Gao 2023 — Allopregnanolone-GABA_A Receptor Sensitivity in PMDD PathogenesisQian Gao, Wei Sun, Yue-Rui Wang et al. · 2023Open reference 1 ↓[2]Itriyeva 2022 — PMS and PMDD in Adolescents (Review)Khalida Itriyeva · 2022Open reference 2 ↓
Brexanolone (IV allopregnanolone) is FDA-approved for postpartum depression; zuranolone (oral) extends this to MDD.[3]Sundström-Poromaa 2023 — New Pharmacological Approaches to PMDD ManagementInger Sundström-Poromaa, Erika Comasco · 2023Open reference 3 ↓ Postpartum depression correlates with the precipitous drop in allopregnanolone at delivery.[4]Suryawanshi 2022 — A Comprehensive Review on Postpartum DepressionOm Suryawanshi, Sandhya Pajai · 2022Open reference 4 ↓
Microbiome Connection#
The Gut Microbiome modulates steroid hormone metabolism including progesterone→allopregnanolone conversion. GABA-producing bacteria (Lactobacillus, Bifidobacterium) interact with the GABAergic system that allopregnanolone modulates—a microbiome-neurosteroid-neurotransmitter axis. Dysbiosis-driven Metal-Driven Inflammation (elevated IL-6, TNF-alpha) alters neurosteroid synthesis enzyme expression.
Cross-References#
- GABA (Gamma-Aminobutyric Acid)—allopregnanolone modulates GABA-A receptors
- Serotonin—complementary neuroactive pathway in PMDD/PPD
- Estrobolome—steroid hormone metabolism by gut bacteria
- Gut-Brain Axis—neurosteroid signaling
References 5
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Qian Gao, Wei Sun, Yue-Rui Wang et al. (2023). Gao 2023 — Allopregnanolone-GABA_A Receptor Sensitivity in PMDD Pathogenesis. Frontiers in Psychiatry.
- 2
Khalida Itriyeva (2022). Itriyeva 2022 — PMS and PMDD in Adolescents (Review). Current Problems in Pediatric and Adolescent Health Care.
- 3
Inger Sundström-Poromaa, Erika Comasco (2023). Sundström-Poromaa 2023 — New Pharmacological Approaches to PMDD Management. CNS Drugs.
- 4
Om Suryawanshi, Sandhya Pajai (2022). Suryawanshi 2022 — A Comprehensive Review on Postpartum Depression. Cureus.
- 5
Bo Liu, Guangbin Wang, Dongmei Gao et al. (2014). Liu 2014 — GABA and Glutamate-Glutamine Alterations in PMDD (3T MRS). Psychiatry Research: Neuroimaging.
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Published page changes
This record shows only material changes published on this page, including changes to its content, evidence, conclusions, or author context. Internal processes and discussion activity are excluded. Pending, declined, and withdrawn proposals remain private.
- published revision
Revised “Microbiome Connection”: now reads “modulates — a microbiome-neurosteroid-neurotransmitter axis. - dysbiosis-driven inflammation (elevated IL-6, TNF-alpha) alters neurosteroid”.
Revised “Microbiome Connection”: changed “modulates — a microbiome-neurosteroid-neurotransmitter axis. - Dysbiosis-driven inflammation (elevated IL-6, TNF-alpha) alters neurosteroid” to “modulates — a microbiome-neurosteroid-neurotransmitter axis. - dysbiosis-driven inflammation (elevated IL-6, TNF-alpha) alters neurosteroid”. · Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Created “Allopregnanolone”: Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid metabolite of progesterone that is the most potent endogenous positive allosteric modulator of GABA-A receptors. It is central to the…
Created “Allopregnanolone”: Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid metabolite of progesterone that is the most potent endogenous positive allosteric modulator of GABA-A receptors. It is central to the… Published sections: Overview; PMDD and PPD; Microbiome Connection; Cross-References. · WikiBiome Deploy Bot · +43 −0
Inspect exact Git diff ↗
